| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -6,170 | -19,940 | -38,730 | -20,320 | -10,880 |
| Net Income Growth | +69.06% | +48.52% | -90.60% | -86.76% | -11,988.89% |
180 Life Sciences Corp (ATNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
180 Life Sciences Corp. is a clinical-stage biotechnology company. It is focused on the development of novel drugs for unmet needs in inflammatory diseases, fibrosis and pain. 180 Life Sciences Corp., formerly known as KBL Merger Corp. IV, is based in MENLO PARK, Calif.